Humacyte is proud to announce that the FDA has granted full approval for Symvess™, a first-in-class, universally implantable, bioengineered human vessel for extremity vascular trauma replacement and repair. This approval is a significant milestone in regenerative medicine, offering a new treatment option for patients with severe arterial injuries. Congratulations to our incredible team and partners who made this possible! Learn more at symvess.com See the Prescribing Information, including Boxed Warning: bit.ly/4dl5tuL INDICATION SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. IMPORTANT SAFETY INFORMATION BOXED WARNING: GRAFT FAILURE -Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage. CONTRAINDICATIONS DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries. WARNINGS & PRECAUTIONS -Graft Rupture: Vascular graft rupture has occurred in patients treated with SYMVESS. Advise patients that arterial bleeding can be life-threatening and to seek emergent medical evaluation for any signs or symptoms of graft rupture such as bleeding, pain and swelling in the extremity, or signs of extremity ischemia. Follow appropriate procedures for handling and administering SYMVESS. -Anastomotic Failure: Anastomotic failure has occurred in patients treated with SYMVESS. In clinical studies of SYMVESS, anastomotic failure occurred within the first 36 days post-implantation. Monitor patients for signs of anastomotic failure such as pain and swelling at the surgical site, decreasing hemoglobin or other signs and symptoms of bleeding. Advise patients to seek urgent medical evaluation if they have any signs or symptoms that may be indicative of anastomotic failure such as bleeding, swelling or worsening pain at the surgical site or changes in color of overlying skin. Follow appropriate procedures for handling and administering SYMVESS. -Thrombosis: Thrombosis has occurred in patients treated with SYMVESS. In clinical trials of SYMVESS, patients received antiplatelet therapy following implantation of SYMVESS to reduce the risk of thrombosis. The risk of thrombosis may increase in patients who discontinue antiplatelet therapy. Anti-platelet therapy is recommended following treatment with SYMVESS. -Transmission of Infectious Diseases: SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or infectious agents. The cells used in the manufacture of SYMVESS are derived from a donor who met the donor eligibility requirements for transmissible infectious diseases. Animal-derived reagents are tested for animal viruses, bacteria, fungi, and mycoplasma before use, but this does not eliminate the risk of transmitting these or other transmissible infectious diseases and disease agents. No transmissible agent infections have been reported during clinical testing. ADVERSE REACTIONS The most common adverse reactions (≥3%) were thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection. USE IN SPECIFIC POPULATIONS Pediatric Use: The safety and effectiveness of SYMVESS in pediatric patients (0 to 17 years old) have not been established. Geriatric Use: Two patients out of the 54 Extremity Group implanted with SYMVESS as a conduit in Study 1 were aged ≥65 years. The number of patients aged ≥65 years was not sufficient to determine whether they responded differently than younger patients to SYMVESS. #Humacyte #FDAApproval #RegenerativeMedicine #Innovation #Biotech #Firstinclass $HUMA

The AV fistula is the current standard of care for dialysis access, but women have higher rates of maturation failure. That means longer waits for usable access and more time on catheters, which carry serious infection risks. That's why we designed V012, the first randomized trial to compare our acellular tissue engineered vessel (ATEV) head-to-head with AV fistula in women. ✅220 vs. 129 catheter-free days in the first year with ATEV vs. AV fistula ✅1.7 months for ATEV vs. 5.3 months for AV fistula as the median time to functional access ✅Even among strong fistula candidates, ~1 in 3 fistulas never matured in year one. ATEV didn’t make them wait. Next, we plan to submit a supplemental BLA to the FDA this quarter to expand the Symvess® label to include hemodialysis access. You can read our press release here: investors.humacyte.com/news-… #ASNKidneyWeek #Nephrology #Dialysis #VascularAccess #WomensHealth PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at bit.ly/4dl5tuL INDICATION SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. BOXED WARNING: GRAFT FAILURE: Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage. DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution. WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing. ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection. Trademarks are property of Humacyte Global, Inc © 2026 Humacyte Global Inc. All Rights Reserved.

For many women on hemodialysis, the current standard of vascular care can often fail to meet their needs. ❌ About 50% of women’s AV fistulas fail to mature, compared with 37% in men. ❌ 30% of women rely on a catheter for dialysis, compared with 24% of men. ❌ Women face twice the risk of catheter dysfunction. That’s why we designed V012, a Phase 3 randomized trial focused only on women. Today, Thursday, October 22nd at ASN Kidney Week in Denver, Dr. Prabir Roy-Chaudhury of the UNC Kidney Center presents interim results comparing our acellular tissue engineered vessel (ATEV) with the AV fistula in a late-breaking oral session. #KidneyWk #Nephrology #Hemodialysis #WomensHealth #VascularAccess

Women on dialysis are more likely than men to face fistula failure and catheter dependence. Humacyte’s interim Phase 3 V012 results evaluating ATEV for hemodialysis access in women will be presented at #KidneyWk on Thursday, 10/22, 4:40 PM MT.

Congratulations to Dr. Bo Allen and the team at Ballad Health and Holston Valley Medical Center on Dr. Allen's first Symvess® procedure. With Dr. Allen joining Dr. Shardul Nagre and Dr. H. Richard Yoon in performing Symvess procedures, Ballad Health continues to expand patient access to innovative treatment options and advance vascular care in the community. Thank you to the surgeons, nurses and multidisciplinary care teams who made these milestones possible. #HealthcareInnovation #MedicalExcellence Learn more here: symvess.com. PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at bit.ly/4dl5tuL INDICATION SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life-threatening hemorrhage. DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution. WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing. ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Momentum for Symvess® continues to build. Hospitals that have ordered Symvess increased 44% in Q3, from 34 to 49, alongside growing utilization and surgeon interest. Learn more about our commercial progress: Read the update (bit.ly/3WbjFTk) #Symvess #Humacyte #VascularSurgery #VascularTrauma PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at bit.ly/4dl5tuL INDICATION SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. BOXED WARNING: GRAFT FAILURE: Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage. DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution. WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing. ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection. Trademarks are property of Humacyte Global, Inc © 2026 Humacyte Global Inc. All Rights Reserved.

Exciting news: Results from our Phase 3 V012 trial of ATEV in women requiring hemodialysis access have been accepted for presentation in a late-breaking oral session at #ASNKidneyWeek 2026, a leading forum for kidney health professionals. #ClinicalResearch #KidneyHealth Read the press release here: bit.ly/4yK4wXt

A new milestone for Symvess® in Florida. Last week, Dr. Geoff Risley of Coastal Vascular and Interventional performed the first commercial Symvess® case at Sacred Heart Emerald Coast in Destin. Thank you to Dr. Risley and the entire clinical team for helping to expand access to this important treatment option for patients. #HealthcareInnovation #MedicalExcellence PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at bit.ly/4dl5tuL INDICATION SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life-threatening hemorrhage. DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution. WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing. ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Humacyte welcomes Scott Coward and Paul Kuznik to our Board of Directors. Their extensive leadership experience across life sciences, commercialization, governance, and medical technology will help guide our next phase of growth. Learn more: investors.humacyte.com/news-… $HUMA #Biotech #Leadership #BoardOfDirectors

Attending the Western Vascular Society Annual Meeting today? Join us for a Lunch Symposium featuring Lisa F. Bennett, MD, MSCS, RPVI, today at 12:55 PM!

Stop by and see the Humacyte team at the Western Vascular SocietyMeeting this weekend, September 26 – 29!

REMINDER: Attending the Eastern Vascular Society Annual Meeting today? Join us for a Technology Forum presentation with Lisa F. Bennett, MD, MSCS, RPVI, today at 4:30 PM in the Grand Ballroom. Visit the Humacyte team to learn more about Symvess® acellular tissue engineered vessel and its use in extremity arterial injury.

If you are attending one of the September Vascular and Surgical meetings, come see the Humacyte team. Visit our booth, connect with our team, experience hands-on opportunities to handle, cut, and suture Symvess, and attend sponsored presentations to learn more about Symvess as a treatment option for extremity arterial injury when autologous vein graft is not feasible. We look forward to connecting with attendees at Eastern Vascular Society, Virginia Vascular Society, AAST, Midwestern Vascular Society, Georgia Vascular Society, and Western Vascular Society. Join us for a Technology Forum presentation at the Eastern Vascular Society with Lisa F. Bennett, MD, MSCS, RPVI, Thursday 9/17 at 4:30 PM in the Grand Ballroom.

A significant commercial milestone: FDA authorization extends #Symvess shelf life to 36 months, supporting hospital preparedness while maintaining the same storage requirements. Learn more: bit.ly/4xkLF3Q INDICATION SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. IMPORTANT SAFETY INFORMATION GRAFT FAILURE: Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage. CONTRAINDICATIONS DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries. WARNINGS & PRECAUTIONS Graft Rupture: Vascular graft rupture has occurred in patients treated with SYMVESS. Advise patients that arterial bleeding can be life-threatening and to seek emergent medical evaluation for any signs or symptoms of graft rupture such as bleeding, pain and swelling in the extremity, or signs of extremity ischemia. Follow appropriate procedures for handling and administering SYMVESS. Anastomotic Failure: Anastomotic failure has occurred in patient treated with SYMVESS. In clinical studies of SYMVESS, anastomotic failure occurred within the first 36 days post-implantation. Monitor patients for signs of anastomotic failure such as pain and swelling at the surgical site, decreasing hemoglobin or other signs and symptoms of bleeding. Advise patients to seek urgent medical evaluation if they have any signs or symptoms that may be indicative of anastomotic failure such as bleeding, swelling or worsening pain at the surgical site or changes in color of overlying skin. Follow appropriate procedures for handling and administering SYMVESS. Thrombosis: Thrombosis has occurred in patients treated with SYMVESS. In clinical trials of SYMVESS, patients received antiplatelet therapy following implantation of SYMVESS to reduce the risk of thrombosis. The risk of thrombosis may increase in patients who discontinue antiplatelet therapy. Anti-platelet therapy is recommended following treatment with SYMVESS. Transmission of Infectious Diseases: SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or infectious agents. The cells used in the manufacture of SYMVESS are derived from a donor who met the donor eligibility requirements for transmissible infectious diseases. Animal-derived reagents are tested for animal viruses, bacteria, fungi, and mycoplasma before use, but this does not eliminate the risk of transmitting these or other transmissible infectious diseases and disease agents. No transmissible agent infections have been reported during clinical testing. ADVERSE REACTIONS The most common adverse reactions (≥3%) were thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection. USE IN SPECIFIC POPULATIONS Pediatric Use: The safety and effectiveness of SYMVESS in pediatric patients (0 to 17 years old) have not been established. Geriatric Use: Two patients out of the 54 Extremity Group implanted with SYMVESS as a conduit in Study 1 were aged ≥65 years. The number of patients aged ≥65 years was not sufficient to determine whether they responded differently than younger patients to SYMVESS. Please see full Prescribing Information at symvess.com, including Boxed Warning, for Symvess.

This #VascularNursesWeek, we recognize the nurses whose expertise, compassion, and dedication support patients through treatment, recovery, and healing. Thank you for all you do. #NursesWeek #VascularCare #HealthcareHeroes

🚨 Happening Tonight! Don't miss this exclusive SVS Women's Section educational webinar on AV Access in women. Hear from: • Laura E. Niklason, MD, PhD, CEO, Humacyte • Lisa F. Bennett, MD, Denver, CO • Young M. Erben, MD, Jacksonville, FL